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Abstract
Background
To evaluate the clinical outcomes 12 months after systemic administration of amoxicillin
(AMX) and metronidazole (MET) adjunctive to subgingival debridement (SD) in patients with
severe chronic periodontitis (sChP).
Material and methods
102 patients with sChP were treated randomly as follows: SD within 2 consecutive days and
placebo for 7 days (group A), SD+AMX+MET (both 500mg x3 times daily TID) for 3 days
(group B), SD+AMX+MET (both 500mg x 3 TID) for 7 days (group C). At baseline, at 3-, 6-,
and 12-months post-treatment probing pocket depth (PD), clinical attachment level (CAL),
furcation involvement, bleeding on probing (BOP), full-mouth plaque score (FMPS) were
determined. The reduction in the number of sites with PD6mm was defined as main out-
come variable.
Results
75 patients completed the study. At 12 months, all three treatment groups showed statisti-
cally significant improvements (p<0.001) of mean PD, CAL, BOP and number of sites with
PD6mm compared to baseline. Mean residual PD were statistically significantly lower and
CAL gain statistically significantly greater in the two antibiotic groups as compared to pla-
cebo. While PD reductions (p = 0.012) and CAL gain (p = 0.017) were statistically signifi-
cantly higher in group C compared to group A, only the 3-day AB group showed statistically
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significantly fewer sites with PD6mm at 12 m (p = 0.003). The reduction in the number of
sites with PD6 mm (primary outcome) showed no statistical significant differences
between the 3 treatment groups. However, in both antibiotic groups significantly more
patients compared to the placebo group reached a low risk for disease progression at 12
months (4 sites with PD5mm).
Conclusion
At 12 months, both adjunctive antibiotic protocols resulted in statistically significantly greater
clinical improvements compared to placebo.
Introduction
It is widely accepted that chronic periodontitis (CP) is a plaque-induced inflammatory disease,
that affects tooth-supporting structures. If left untreated, the progressive destruction of these
tissues may ultimately result in tooth-loss [1]. Therefore, the main focus of periodontal therapy
is the removal of bacterial deposits from the root surfaces through mechanical debridement
[i.e. scaling and root planning (-SRP)] aiming at resolving the inflammation, arresting disease
progression and re-establishing periodontal health. Several authors provided evidence that
persistence of Aggregatibacter actinomycetemcomitans (A.actinomycetemcomitans), Porphyro-
monas gingivalis (P. gingivalis) and some other bacterial species are associated with the pro-
gression of tissue destruction [2–4] while better clinical outcomes were obtained when these
bacteria were undetectable [5–7]. Therefore, reduction or even complete eradication of the
microbial load seems to be a necessity for obtaining long-term clinical stability [8, 9].
In order to accomplish these goals, non-surgical periodontal therapy is frequently com-
bined with adjunctive antibacterial agents i.e. antibiotics and antiseptics [3, 10–13]. A large
number of studies provided evidence indicating that the adjunctive use of Amoxicillin (AMX)
and Metronidazole (MET) to SRP had positive effects on the suppression of A. actinomycetem-
comitans and other periodontopathogenic bacteria from periodontally compromised sites [14–
18]. Statistically and clinically significantly better clinical outcomes in terms of probing pocket
depth (PD) reduction and clinical attachment level (CAL) gain were observed when the com-
bination of AMX + MET was administered adjunctively to SRP compared to treatment with
SRP alone [10, 11, 19–29]. Additionally, this adjunctive antibiotic treatment regimen yielded a
statistically significant reduction of periodopathogenic bacteria and of inflammatory cytokines
compared to SRP alone [19–31].
Even though a large variety of studies focused on the clinical, microbiological and inflamma-
tory effects of the adjunctive use of AMX and MET to SRP, no consensus exists regarding the
optimal dosage and duration of these antibiotics. While some authors have investigated the
adjunctive administration of 375 mg AMX and 250/500 mg MET 3 TID for 7–8 d to SRP [19–
21, 32, 33], others have evaluated the effect AMX and MET in a dosage of 500 mg 3 TID for 7 d
[18, 22, 29], or 500 mg AMX and 400/250 mg MET 3 TID for 10 to 14 d [17, 23–27, 34]. Since
several side effects such as change of taste, headache, diarrhoea, nausea/vomiting, hypersensitiv-
ity, renal and liver toxicity, etc., have been reported following the intake of antibiotics over a
longer period (e.g. up to 7 days and longer) [19, 35, 36], it appears important that antibiotics are
taken in a minimum bactericidal concentration for a minimum duration [37]. It has been sug-
gested that such concepts may maximize the positive effects of antibiotics by limiting the occur-
rence of the mentioned side effects. Moreover, the use of a high antibiotic concentration for a
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short-time, may decrease the possibility to develop microbial antibiotic resistance. Additionally,
long-time antibiotic protocols may bare a higher risk for a patient to become non-compliant
and patient compliance with unsupervised intake of prescribed medication is important for
therapy success [38, 39].
Bacterial resistance to antibiotics has been a recognized problem almost from the begin-
nings of the antibiotic era showing a continuous global increase [40–43]; however, only in the
last 20 years, emergence of dangerous, resistant strains with an impact on the success of anti-
microbial therapy of life-threatening infections was regularly registered [44, 45]. Antibiotic-
resistant infections have a tremendous negative impact on public health and economy: i.e. in
the United States, yearly, 2 million people are infected with antibiotic-resistant bacteria and 23
000 die of these infections [46]; furthermore, additional care costs are estimated at 1.6 billion €
and 2.5 million € additional hospital days in Europe [45, 47] and 20 billion $ and 8 million $
additional hospital days in US [45, 46, 48]. New resistant strains or resistant factors within bac-
terial populations can appear especially when low drug doses are prescribed, resulting in poor
drug compliance or incomplete penetration of the drug to all tissues [49–51]. Nonetheless,
studies investigating antimicrobial resistances observed a decline in resistance frequencies
after antibiotic removal [52–54]. Additionally, only a transient increase in the percentage of
resistant subgingival species was observed when the antibiotic administration increased, at 90
days after antibiotic therapy the percentage of antibiotic-resistant strains having returned to
baseline values [53].
Considering the deleterious effects of prolonged courses of antibiotic therapy (e.g.
adverse infections, poor patient compliance, evolution and dissemination of antibiotic
resistant organisms, additional high costs and hospitalisation), scientists/doctors in several
areas in general medicine tried to optimize the duration of the therapy emphasising the
optimal antibiotic combination [55], the implementation of shorter, high-dosage treatment
regimes [55–63].
In periodontal therapy, controlled clinical studies evaluating the potential efficacy of a
short-term administration of AMX and MET compared to the standard protocol (e.g. use for
at least 7 days) are absent. We recently evaluated the clinical outcomes of a 3-day regimen of
AMX and MET adjunctive to SRP in severe chronic periodontitis at 6 months showing that
both 3 and 7 days adjunctive administration of these antibiotics led to statistically significant
better clinical improvements compared to SRP alone at 6 months [11]. However, at present, it
is unknown to what extent the results obtained with the short-term administration of AMX
and MET remain stable over a longer period of time (e.g. up to one year).
The aim of the present study was therefore to evaluate the clinical outcomes obtained at 1
year following non-surgical periodontal therapy (performed within 2 consecutive days) in con-
junction with systemic administration of AMX and MET for 3 or 7 days in patients with severe
chronic periodontitis (sCP).
Material and methods
This study was designed as a randomized, placebo controlled, double-masked clinical trial test-
ing the hypothesis that “the systemic use of AMX and MET administered for 3 or 7 days as
adjunct to SD leads to superior clinical results compared with SD alone” [11].
The power of the study was calculated considering a difference of at least 5 sites with a
PD 6 mm [26, 27, 64] and a standard deviation of 6 sites [19, 27] between both AB and pla-
cebo groups, respectively. A study power of 92% for a statistical significance level of 0.05 was
reached for 30 subjects per treatment group; however, taking into account a possible attrition
of 13% we recruited 34 patients per treatment group.
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Approval of the Ethical Committee of the Faculty of Medicine and Pharmacy of Cluj-
Napoca (Application #514/09.01.2012, approved at 09.01.2012) was obtained for the study pro-
tocol, which was conducted according to the Declaration of Helsinki (1964, revision 2008).
The study was registered in the ISRCTN trial registry (study ID ISRCTN17605083). Since
patient recruitment began in January 2012, and at that time trial registration wasn‘t mandatory
for many journals, the trial was registered with delay after enrolment of participants has
started. The authors confirm that all ongoing and related trials for this drug/intervention are
registered.
Subjects
The clinical protocol was presented in detail previously [11]. Briefly, 102 subjects seeking den-
tal treatment at the Dental University Clinic (University “Iuliu Hatieganu”, Cluj-Napoca) were
included and treated as follows: patient recruitment lasted between 10.01.2012–01.03.2014,
subgingival debridement was performed between 20.01.2012–30.06.2014 and the follow-up
period was between 03.02.2012 (2 weeks post debridement)– 05.06.2015. Following inclusion
criteria were considered: age over 30 years, patients had to present at least 12 natural teeth in
the oral cavity, with clinical (at least one site/quadrant with PD6mm) and radiographic
signs of generalized severe chronic periodontitis [65], good level of oral hygiene (Full-mouth
plaque scores 25% prior SD) [66], systemically healthy with no history of diseases that may
influence the severity/progression of periodontitis (e.g. Down Syndrome, HIV, Diabetes Melli-
tus type 1 and 2), no post-iradiation in the head/neck area, no infectious/heart diseases that
need prophylactic administration of antibiotics before dental treatments, absence of liver dis-
eases. Subjects smoking at least 10 cigarettes per day for the last five years were defined as
smokers [67]. Patients that had non-surgical periodontal therapy within the previous 12
months, had systemic or local antibiotic therapy within the preceding 3 months, under medi-
cation that may have interacted with AMX or MET (e.g., coumarin derivatives, containing
alcohol derivatives, 5-fluor-uracyl/ disulfiram derivatives, amprenavir oral solutions, lopina-
vir/ritonavir oral solution) or under medication with a possible influence on the periodontium
(Ciclosporin A, compounds of Phenytoin, calcium channel blockers), or pregnant/lactant
patients were excluded from the study. All eligible subjects were thoroughly informed of the
aim, risks and benefits of their participation to the study as well as the treatment protocol, and
informed written consent to participate in the study was obtained from all participants prior
study commencement.
Clinical protocol
According to a computer generated list, all included subjects were allocated to one of the three
treatment groups: control group A receiving SD + placebo [placebo thrice a day (TID) for 7
days; group B treated with SD and adjunctive systemic AMX+MET (both antibiotics 500 mg
TID for 3 days, placebo TID for the rest 4 days; and group C treated with SD and systemic
AMX+MET (both antibiotics 500 mg TID for 7 days (Fig 1). Allocation concealment was war-
ranted by the use of opaque envelopes.
Prior to SD (baseline), at 3, 6 and 12 months after SD the following parameters were
assessed using a manual periodontal probe (PCPUNC 15, Hu Friedy, Chicago, IL, USA):
FMPS [66], bleeding on probing (BOP) [68], probing pocket depth (PPD) and clinical attach-
ment level (CAL). Additionally, furcation involvement (FI) was also measured using a manual
furcation probe (Nabers probe -PQ2N, Hu Friedy, Chicago, IL, USA). Sessions including oral
hygiene instruction and supragingival cleaning were performed until patients reached a
FMPS 25%. All clinical recordings and oral hygiene instructions were performed by one
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single examiner (RJ) blinded to treatment allocation. Subsequently, SRP was performed within
2 consecutive days by one experienced periodontist (RC) also blinded to group allocation. All
sites with PD 4mm were scaled and root-planed to the bottom of the pocket with machine
driven scalers (Kavo Sonicflex Scaler, Kavo Dental GmbH, Biberbach, Germany) and Gracey
curets (Hu Friedy, Chicago, IL, USA). Treated pockets were then thoroughly rinsed with
0.12% chlorhexidine digluconate solution. For 14 days, subjects rinsed with a 0.2% chlorhexi-
dine digluconate solution (Corsodyl1, GlaxoSmithKline, Brentford, London, UK, twice daily
for 2 minutes) and brushed their teeth with 0.2% chlorhexidine digluconate tooth paste (Elu-
gel1, Pierre Fabre, Paris, France). At the end of the SD sessions, patients were allocated by
another clinician (RT) to one of the three treatment groups, received their medications and
intake instructions (for detailed description about the bottle pills see [11]). Two weeks follow-
ing SD, patients were asked about compliance with study medication and possible adverse
effects after pills intake. Subsequently, patients were recalled at 3, 6 and 12 months when the
following parameters were assessed: FMPS, BOP, PD, CAL, FI. At these appointments, only
supragingival calculus was removed leaving any residual periodontal pockets with PD = 4 mm
and BOP or PD5 mm without re-instrumentation.
Five patients, each with minimum 10 teeth with at least one site with PD 6 mm per tooth,
were used to calibrate the examiner. Patients were examined twice on 2 appointments, 48
hours apart. Calibration was accepted when these measurements were similar to the millimetre
at>90% (mean intra-examiner reliability: PD: 0.87, CAL: 0.76, Cohen‘s Kappa Analyses). The
examiner was blinded to the treatment allocation.
Statistical analyses
All data were introduced into a database (LI) and double-checked for errors by comparison
with the original patients’ charts (RT, RC). Statistical analyses were performed by an experi-
enced professional statistician (CH) using the statistical software programs (SPSS statistics 21,
IBM, Armonk, NY, USA and R Core Team, 2016. R: A language and environment for statisti-
cal computing. R Foundation for Statistical Computing, Vienna, Austria).
The statistical unit was the patient; the primary outcome variable was the reduction (Δ) in the
number of sites per patient with PD 6 mm calculated between baseline and 12 months. Sec-
ondary variables were mean changes in FMPS, BOP, PD, AL, number of sites with PD 6 mm,
with PD 5 mm and total number of sites with PD = 4 positive on probing and sites with
PD5mm at 12 months, as well as the number of subjects reaching a low risk for disease progres-
sion (4 sites with PD5mm) [69]. Statistically significant were considered p-values< 0.05.
Fig 1. Flowchart of the study. FMPS = full-mouth plaque score; SD = subgingival debridement;
ITT = intention to treat analyses; PP = per protocol analyses; m = months.
https://doi.org/10.1371/journal.pone.0179592.g001
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All sites with PD 4 mm at baseline were considered for statistical analyses. Intra-group
clinical comparisons between the follow-ups were analysed by means of Paired t-Test and Wil-
coxon Signed Ranks Test. Comparisons between the groups at the various timepoints were
performed adjusting for baseline values and smoking using ANCOVA and Bonferroni
adjustments.
The residual number of sites with PD5 mm was analysed and according to it patients
were distributed to low (4 sites), moderate (5–8 sites) and high (9 sites) risk for disease pro-
gression [69]. Group comparisons were performed using Fischer‘s Exact Test.
By means of a Poisson regression analysis, the relationship between the number of sites
with PD 6 mm at 12 months and the variables treatment (antibiotics for 3 or 7 days), smok-
ing, gender, BOP, FMPS, at baseline and at 12 months, baseline mean PD, baseline mean AL,
disease severity with10 sites with PD 6 mm at baseline was studied.
Results
Subjects
In total, 102 subjects (mean age 43.37 ± 9.85, 65 female, 35 smokers) fulfilling the inclusion cri-
teria (34 per treatment group) were enrolled in this study and were treated and followed-up
according to the protocol between January 2012 and June 2015. Considering the dropouts dur-
ing the three follow-ups, 27 patients were excluded from the final per protocol (PP) analyses.
Reasons for dropout were: non-compliance with the appointments (n = 16), antibiotic intake
for other medical reasons (n = 9), moved to another town (n = 2). Eventually, 75 subjects
[mean age 42.59 ± 9.68 years, 45 female (60%), 22 smokers (29.33%)] were included in the
final analyses (Fig 1). Patient distribution resulted in no statistically significant differences
between the groups regarding gender, smoking status and baseline clinical parameters (Tables
1 and 2). Patient compliance with the pills intake was assessed at two weeks after SD and out-
lined excellent compliance with only some minor time-interval differences [11]. Adverse
events occurring during or after the medication period were registered in all treatment groups:
1–2 patients in each treatment group had headaches, musculoscheletal pain, taste disorders
and vertigo; 1 patient in placebo- and in group B complained about gastrointestinal disorders,
while I patient in placebo and 1 in group C had fever. Only 1 patient in group B had respiratory
disorders and I patient in the placebo group complained about shivering. None of the patients
had signs of allergy nor candida [11].
Clinical findings
Clinical findings at 3 and 6 months after non-surgical periodontal treatment were reported in
a previous publication [11]. At 6 months, 91 of the 102 included subjects completed the evalua-
tion and statistically significant clinical improvements (p<0.05) compared to baseline were
observed in all treatment groups for all evaluated clinical parameters. These statistically signifi-
cant improvements were maintained up to one year in all three groups, even if fewer subjects
(75 out of 102 subjects) completed the study (p<0.05, paired t-Test and Wilcoxon Signed
Ranks Test). At baseline, no statistically significant differences between the treatment groups
were registered for any of the investigated clinical parameters (Tables 1 and 2, p>0.05). BOP
was statistically significantly reduced in all treatment groups compared to baseline. However,
no statistically significant differences between the groups were seen at baseline and at 12
months. In all three groups, FMPS shoved a statistically insignificant increase at 12 months
compared to baseline, without any inter-group differences (Table 2).
At 12 months, both antibiotic groups resulted in statistically significant improvements
compared to the placebo group regarding the total mean PD as well as the mean PD and PD
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reductions (Δ base-12m) for sites with PD 4-6mm and deep sites with PD7mm (Table 2).
Total mean PD reductions (Δ base-12m) were significantly higher only in group C compared
to group A. CAL gain (Δ base-12m) at 12 months was significantly higher in the 7-day AB
group compared to placebo for all sites with PD4mm as well as for sites with PD 4-6mm.
However, for sites with PD7mm no statistically significant differences were observed
between the three groups. Furthermore, at 12 months, the 3-day AB group showed signifi-
cantly less sites with PD6mm, with PD5mm and with PD = 4mm and BOP+ compared to
the control group (Table 2). Nonetheless, the reduction in the number of sites with PD6 mm
(the primary outcome variable), showed no statistical differences between the three patient
groups. No statistically significant changes were seen for any of the evaluated clinical parame-
ters between the two antibiotic groups (p>0.05).
At 12 months, smokers exhibited statistically significantly less improvements compared to
non-smokers with respect to mean PD and significantly less PD reductions, mean CAL and
mean CAL gain in all PD categories (p<0.05, Table 2). For sites with PD7mm, smokers had
significantly higher mean PD and CAL at 12 months; however there were no statistically sig-
nificant differences for PD reduction and CAL gain (p>0.05, Table 2). Moreover, smokers
showed less sites with PD5mm and with PD4mm and BOP+ (p<0.05, Table 2).
Analysing the risk for disease progression [69], all patients in all treatment groups were at
baseline at high risk (Table 3). At all follow-ups a decrease was noticed in all treatment groups,
so that at 12 months the lowest percentage (20.8%) of patients being at high risk for disease
progression was observed in the 3-day AB group, followed by the 7-day AB group with 40%
and finally by the placebo group with 46.2%. Comparing the groups regarding the number of
subjects that reached a low risk of disease progression presenting4 sites with PD5mm,
more patients were present in both antibiotic groups as compared to the placebo group
(Table 3). However, in the PP-analyses only the 3-day AB group exhibited significantly more
Table 1. Baseline demographic characteristics (patients included in the PP analysis, PD and CAL val-
ues for all sites).
Variables Group A Group B Group C
N = 26 N = 24 N = 25
Female gender (n/%) 16/61.5 15/62.5 14/56
Age (years) 41.84±10.04 42.37±9.87 43.56±9.46
Smoker (%) 8 8 6
BOP(%) 62.89±27.80 58.89±35.94 71.05±24.39
FMPS (%)
Recruition timepoint 54.29±20.93 52.53±22.46 47.46±23.35
Baseline after OH
instructions
20.37±6.43 17.44±7.21 19.03±5.58
Mean PD (mm) ] 4.54±0.78 4.58±0.72 4.61±0.61
Mean CAL (mm) ] 5.17±1.26 5.13±1.29 5.13±1.12
No. (%) PD4mm 41.88±17.31 (52.65
±13.66)
47.71±18.82 (51.38
±12.97)
47.16±18.87 (45.98
±14.26)
No. (%) PD 4-6mm 41.88±17.31 (52.65
±13.66)
47.71±18.82 (51.38
±12.97)
47.16±18.87 (45.98
±14.26)
No. (%) PD7mm 12.81±12.91 (15.33
±12.67)
12.96±8.93 (14.87
±9.16)
19.20±12.84 (17.75
±9.75)
PD = pocket depth, CAL = clinical attachment level, BOP = bleeding on probing; FMPS = full-mouth plaque
score after O’Leary [66]
]total mean values calculated for all sites, including values <4mm at baseline
https://doi.org/10.1371/journal.pone.0179592.t001
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Table 2. Mean values and group comparisons (ANOVA adjusted for smoking and ANCOVA adjusted for baseline values and smoking for 12
month variables), and their changes (Δ) between baseline and 12 months (mean±SD) (PP analyses, intragroup comparisons between baseline and
12 m by means of Paired t-Test and Wilcoxon Signed Ranks Test).
Variables Group A (SRP
+Placebo)N = 26
Group B (SRP
+AB 3d) N = 24
Group C (SRP
+AB 7d) N = 25
Group comparisons Smoker—Non-
smoker P valuep value
groups A-B
p value
groups A-C
p value
groups B-C
Δ No. PD6 mm
baseline- 12m 20.31±15.81 hs 27.71±15.00 hs 31.40±17.67 hs 0.313 0.061 0.100 0.226
PD (mm)
Baseline 5.43±0.61 5.43±0.51 5.75±0.59 1.000 0.180 0.196 0.197
12 m 3.31±0.42hs 2.91±0.46 hs 3.00±0.56 hs 0.011s 0.047s 1.000 0.034s
Δ baseline- 12m 2.04±0.71 2.55±0.65 2.67±0.80 0.057 0.012s 0.843 0.016s
CAL (mm)
Baseline 5.91±1.26 5.82±1.23 6.10±1.25 1.000 1.000 1.000 0.640
12 m 4.67±1.18 s 4.26±1.23 hs 4.29±1.17 hs 0.317 0.451 0.959 0.004s
Δ baseline- 12m 1.20±0.73 1.59±0.65 1.71±0.54 0.093 0.017s 0.789 0.009s
BoP (%)
Baseline 62.83±27.80 58.89±35.94 71.05±24.39 1.000 0.981 0.473 0.929
12 m 12.91±10.01 hs 10.08±7.13 hs 10.95±9.16 hs 0.769 1.000 1.000 0.480
Δ baseline- 12m 51.92±25.51 48.81±36.24 60.10±28.23 1.000 1.000 0.585 0.852
FMPS (%)
Baseline 20.37±6.43 17.44±7.21 19.03±5.58 0.352 1.000 1.000 0.209
12 m 20.74±12.93 33.49±24.21s 30.01±19.87s 0.032 0.256 1.000 0.097
Δ baseline- 12m -0.94±12.23 -16.08±22.92 -10.98±19.99 0.020 0.227 0.914 0.120
PD 4–6 mm (mm)
Baseline 4.88±0.22 4.89±0.22 4.96±0.22 1.000 0.611 0.846 0.880
12 m 3.06±0.36 2.74±0.39 2.77±0.48 0.016s 0.047s 1.000 0.007s
Δ baseline- 12m 1.82±0.39 2.15±0.46 2.19±0.50 0.027s 0.018s 1.000 0.018s
CAL of PD 4–6 mm
(mm)
Baseline 5.49±1.13 5.32±1.17 5.40±1.06 1.000 1.000 1.000 0.217
12 m 4.41±1.06 4.03±1.23 3.95±1.15 0.282 0.031s 1.000 0.013 s
Δ baseline- 12m 1.07±0.59 1.29±0.52 1.46±0.44 0.382 0.039s 1.000 0.027s
PD >7 mm (mm)
Baseline 7.60±0.54 7.61±0.67 7.82±0.88 1.000 0.826 0.910 0.779
12m 4.44±1.06 3.60±0.93 3.70±0.96 0.009s 0.043s 1.000 0.011s
Δ baseline- 12m 3.15±1.26 4.01±0.96 4.12±1.49 0.036s 0.016s 1.000 0.193
CAL of PD >7 mm
(mm)
Baseline 7.70±0.92 7.96±1.54 7.79±1.41 1.000 1.000 1.000 0.110
12 m 5.62±1.29 5.34±1.65 5.26±1.46 0.110 0.405 1.000 0.037s
Δ baseline- 12m 1.98±1.21 2.67±1.12 2.42±0.79 0.065 0.424 1.000 0.101
No. PD6mm
Baseline 25.50±17.36 29.37±14.65 35.92±17.58 1.000s 0.098 0.592 0.408
12 m 5.19±3.71 hs 1.66±2.26 hs 4.52±5.40 hs 0.003s 0.917 0.068 0.093
No. PD5mm
Baseline 41.73±19.91 46.21±18.65 53.24±20.65 1.000 0.129 0.665 0.989
12 m 10.50±6.85 4.71±5.40 8.44±8.92 0.004s 0.453 0.202 0.003s
Δ baseline- 12m 31.23±17.48 41.50±18.67 44.80±21.37 0.180 0.050 1.000 0.269
No. PD = 4 mmBOP
+ and PD5mm
(Continued)
Short-term antibiosis in non-surgical periodontal therapy
PLOS ONE | https://doi.org/10.1371/journal.pone.0179592 June 29, 2017 8 / 20
patients with low risk at 12 months compared to the placebo group with no significant differ-
ences between groups B and C (Table 4). The difference between groups A and C was only
present in the ITT population (p = 0.049). A Bonferroni correction (3 tests comparing groups
A-B, A-C, B-C) would lead to significant differences only between groups A and B (ITT and
PP).
At 12 months, the regression analysis showed a statistically significant positive correlation
between the residual number of sites with PD6mm and the placebo group (group B had 0.28
and group C 0.70 times the expected number of residual sites with PD6mm at 12 months
than group A), male gender and smokers. Further significant variables were percentage of
BOP at baseline and at 12 months, baseline elevated level of BOP and initial mean CAL
(Table 5).
Discussion
The present study evaluated the 12 months clinical outcomes following a 3 or 7 days systemic
administration of AMX and MET adjunctive to SD as compared with non-surgical periodontal
treatment alone in patients with severe ChP. A 3-day systemic administration of AMX and
MET yielded comparable clinical outcomes as a 7-day AMX and MET regimen as an adjunct
to SD.
Since several clinical trials have evaluated different administration periods for antibiotics
adjunctive to non-surgical periodontal therapy, like of 7 [19, 22, 29, 70] to 14 days [17, 26, 27,
71] and no consensus regarding the optimal antibiotic regimen exists, the aim of the present
study was to provide additional data for determining the optimal antibiotic dosage and dura-
tion adjunctive to the non-surgical periodontal treatment. Bearing in mind the fact that possi-
ble emergence of new resistant strains may occur during or after a single long-term infection
associated with antibiotic therapy and considering the widespread use of antibiotics in our
society, antimicrobial resistance became nowadays a global burden [49, 50]. As several areas in
general medicine succeeded in restricting and optimizing as much as possible the antibiotic
regimen by reducing the duration of antibiotic intake and increasing the dosage [55–57, 63,
72] it seems appropriate that similar measures should be taken in dentistry, restricting antibi-
otic treatment to patients with the most benefit from it and setting an optimal treatment
regime (minimum bactericidal concentration and duration) [37]. Moreover, this should be
one of the main aims in research since a significant increase in the proportion of resistant
strains to the most common used antibiotics in dentistry, especially to AMX and MET which
have been shown to be most effective in treating severe forms of periodontitis, had already
been registered [73–79]. Considering these aspects and knowing that the dissemination of
Table 2. (Continued)
Variables Group A (SRP
+Placebo)N = 26
Group B (SRP
+AB 3d) N = 24
Group C (SRP
+AB 7d) N = 25
Group comparisons Smoker—Non-
smoker P valuep value
groups A-B
p value
groups A-C
p value
groups B-C
Baseline 54.69±22.84 60.66±22.345 66.36±23.24 1.000 0.227 1.000 0.965
12 m 12.34±8.15 6.41±6.25 10.97±8.94 0.012s 1.000 0.153 0.002s
Δ baseline- 12m 42.34±20.85 hs 54.25±21.68 hs 55.44±23.97 hs 0.174 0.137 1.000 0.229
PD = pocket depth, CAL = clinical attachment level, BOP = bleeding on probing; FMPS = full-mouth plaque score after O’Leary [66], m: months, base:
baseline, PP = per protocol analyses
s statistically significant p<0.05 values
hs statistically highly significant p<0.0001.
https://doi.org/10.1371/journal.pone.0179592.t002
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Table 3. Patients (Number and %) with low (4 number of residual sites with PD5mm4), moderate (Number of residual sites with PD5mm:
5–8) and high (Number of residual sites with PD5mm9) risk for disease progression [69].
Risk categories Group A N = 26 (PP)
N = 27 (ITT)
Group B N = 24 (PP)
N = 26 (ITT)
Group C N = 25 (PP)
N = 27 (ITT)
A–B Fisher-
Test
A–C Fisher-
Test
B–C Fisher-
Test
ITT (n = 80)
Baseline - - -
4 sites PD5mm
(n/%)
0 0 0
5–8 sites PD5mm
(n/%)
0 0 0
9 sites PD5mm
(n/%)
30/100 30/100 31/100
3 months 0.001s 0.314 0.053
4 sites PD5mm
(n/%)
2/7.1 15/50 6/21.4
5–8 sites PD5mm
(n/%)
6/21.4 6/20 6/21.4
9 sites PD5mm
(n/%)
20/71.4 9/30.0 16/57.1
6 months <0.001s 0.023s 0.036s
4 sites PD5mm
(n/%)
2/6.7 18/66.7 11/35.5
5–8 sites PD5mm
(n/%)
8/26.7 1/3.7 6/19.4
9 sites PD5mm
(n/%)
20/66.7 8/29.6 14/45.2
12 months <0.001s 0.091 0.264
4 sites PD5mm
(n/%)
6/21.4 18/72.0 13/48.1
5–8 sites PD5mm
(n/%)
8/32.1 2/8.0 4/14.8
9 sites PD5mm
(n/%)
13/46.4 5/20.0 10/37.0
PP (n = 75)
Baseline - - -
4 sites PD5mm
(n/%)
0 0 0
5–8 sites PD5mm
(n/%)
0 0 0
9 sites PD5mm
(n/%)
26/100 24/100 25/100
3 months 0.005 s 0.146 0.262
4 sites PD5mm
(n/%)
2/7.7 11/45.8 6/24.0
5–8 sites PD5mm
(n/%)
4/15.4 4/16.7 6/24.0
9 sites PD5mm
(n/%)
20/76.9 9/37.5 13/52.0
6 months <0.001s 0.004s 0.280
4 sites PD5mm
(n/%)
1/3.8 15/62.5 10/40.0
5–8 sites PD5mm
(n/%)
8/30.8 1/ 4.2 3/ 12.0
9 sites PD5mm
(n/%)
17/65.4 8/33.3 12/48.0
(Continued )
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periodontal pathogens in other body parts may lead to serious life-threatening diseases (such
as brain abscesses, lung infections, endocarditis, soft-tissue infections) [80], it seems of out-
most importance to optimize the adjunctive use of antibiotics in the treatment of periodontal
disease.
While several studies already exist in evaluating and comparing dosages of 250-500mg of
AMX and MET adjunctive to non-surgical periodontal treatment and durations of 7–14 days
[15, 17–19, 22, 26, 27, 29, 32, 71, 81, 82] and showing significant clinical and partly microbio-
logical benefits in the antibiotic groups over the mechanical therapy alone, we found it relevant
to evaluate the effectiveness of a short-treatment antibiotic course of 3 days [11]. However, this
duration might be an issue concerning the development of antimicrobial resistance. Nonethe-
less, we decided to test this antibiotic duration based on the observations from the study of
Feres et al. [53], where a transient increase of the bacterial resistance was shown to be lower in
the 3 day as compared to the 7 day antibiotic regimen. Moreover, favourable results were
obtained for short-treatment courses of acute streptococcal pharyngitis in children [83, 84],
for acute urinary tract infections [85], intra-abdominal infections and infections in general
surgery units [86, 87].
In the present study at 12 months, all treatment groups showed statistically significant
reductions (Δ) in the number of sites with PD6 mm compared to baseline (p<0.05) (primary
outcome variable, Table 2) [11]; no statistically significant differences could be detectable
between the three treatment groups, even though the reductions were higher in the two antibi-
otic groups compared to the control group (Table 2). This may be explained by the fact that in
the present study at 12 months, a higher attrition in the number of patients compared to the
priory calculated study power was observed in all treatment groups (below 30 patients/group
at 12 months) resulting in low power assessments for the primary outcome (post hoc analysis:
for comparison group A-B 35%, for A-C 64%). Wide deviation ranges for the number of sites
with PD6mm at baseline (14. 65–17.58 sites) may have also influenced the fact that no
Table 3. (Continued)
Risk categories Group A N = 26 (PP)
N = 27 (ITT)
Group B N = 24 (PP)
N = 26 (ITT)
Group C N = 25 (PP)
N = 27 (ITT)
A–B Fisher-
Test
A–C Fisher-
Test
B–C Fisher-
Test
12 months 0.001s 0.120 0.164
4 sites PD5mm
(n/%)
5/19.2 17/70.8 11/44.0
5–8 sites PD5mm
(n/%)
9/34.6 2/8.3 4/16.0
9 sites PD5mm
(n/%)
12/46.2 5/20.8 10/40.0
ITT: Intention to treat analyses, PP: per protocol analyses, PD: pocked depth, m: months
https://doi.org/10.1371/journal.pone.0179592.t003
Table 4. Patients reaching a low risk of disease progression (4 sites with PD5 mm) at 12 months.
Timepoints Group A ITT: n = 28
PP: n = 26
Group B ITT: n = 25
PP: n = 24
Group C ITT: n = 27
PP: n = 25
Groups A-B
(Fisher-Test)
Groups A-C
(Fisher Test)
Groups B-C
(Fisher Test)
ITT analysis
(n = 80)
6/21.4% 18/72.0% 13/48.1% <0.001s 0.049s 0.097
PP analysis
(n = 75)
5/19.2% 17/70.8% 11/44.0 <0.001s 0.070 0.080
ITT: Intention to treat analyses, PP: per protocol analyses, PD: pocked depth, m: months
https://doi.org/10.1371/journal.pone.0179592.t004
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significant differences between the 3 groups were obtained for the their reductions (Δ). How-
ever, at 12 months, only the 3-day antibiotic group showed statistically significantly less num-
ber of residual deep sites (PD6mm), as compared to the placebo group (p = 0.003), even
though the placebo group showed at baseline less deep sites (25.5±17.36) compared to the 2
antibiotic groups (3 days AB 29.37±14.65, 7 days AB 35.92±17.58, Table 2). Nonetheless, since
the number of residual deep sites (PD6 mm) was a secondary outcome variable, these results
have to be interpreted with caution. Similar results were obtained also for the residual number
of sites with PD5mm or with PD4mm and BOP+, where only the 3-day AB group showed
statistically significantly less sites compared to placebo. The fact that in the 7-day antibiotic
group the residual number of such sites (with PD6mm, PD5mm, PD4mm and BOP+)
was not statistically significantly lower compared to the placebo group might be related to the
higher number of such sites at baseline in group C as compared to group A [for PD6mm:
placebo 25.50 ± 17.36 (mean±SD), 7 day AB group 35.92±17.58(mean±SD)], even if no statisti-
cally significant differences were obtained between the three treatment groups at baseline
(Table 2).
Our 12-month findings corroborate those obtained by Feres et al., the 3-day AB group in
our study showing comparable residual number of sites with PD6mm (1.66±2.26) to the
14-day AMX and MET group of Feres et al. (1.2±2.2) [27]. Comparable results for deep sites
were also registered by Harks et al., where patients receiving AMX and MET for 7 days showed
at 27.5 months 0.9±1.6% of sites with PD7mm [81] and by Rooney et al. at 6 months (the
AMX+MET group had 1.3±2.6% of sites with PD6mm) [16]. Furthermore, looking at the
number of sites with PD5mm our data are similar to those obtained by Feres et al. at 12
months (Feres et al. AMX+MET group: 4.7±6.0, our study 3-day AB group: 4.71±5.4 sites) and
Silva et al. obtained at 3 months (Silva et al. AMX+MET for 14 days 5.3±4.4) [26, 27]. How-
ever, Cionca et al. showed at 6 months that the AMX+MET group had a residual number of
sites with PD>5mm and BOP+ of 0.4±0.8 [19] much lower than the number of such sites in
both AB groups from our study (group B: 6.41±6.25, group C: 10.97±8.94). As reported previ-
ously, baseline periodontal conditions of the present study differ from those of Cionca et al.
who included patients with moderate to severe ChP with at least four teeth with PD> 4mm
Table 5. Poisson regression analyses for the number of residual sites with PD 6 mm at 12 months after non-surgical periodontal therapy as
related to placebo group (group A).
Variables Exponential Coefficient (eB) 95% CI p value
Group B (ABAb for 3 d) 0.286 0.193–0.424 <0.001s
Group C (ABAb for 7 d) 0.7023 0.526–0.939 0.017s
Female gender 0.6690 0.537–0.887 0.004s
Smoker 1.364 1.057–1.761 0.017s
10 sites with PD6 mm at baseline 1.295 0.837–2.004 0.246
BOP baseline 0.995 0.990–0.999 0.044s
BOP at 12m 1.027 1.013–1.041 <0.001 s
FMPS baseline 0.997 0.991–1.002 0.244
FMPS at 12m 1.000 0.989–1.010 0.933
GBI baseline 0.997 0.961–0.003 0.004
GBI at 12m 0.986 0.973–1.000 0.056
Mean PD baseline 0.890 0.664–1.192 0.433
Mean CAL baseline 1.248 1.077–1.447 0.003s
Ab = antibiotics, PD = pocket depth, CAL = clinical attachment level, BOP = bleeding on probing, GBI: gingival bleeding index [68]s statistically significant p<
0.05. Reference categories are: Group A, Male, Non-Smoker
https://doi.org/10.1371/journal.pone.0179592.t005
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and CAL 2 mm as opposed to generalised severe forms of ChP included in the present study
[11, 19]. This is reflected in the baseline number of sites with PD 5 mm, which was at least
double as high in every treatment group of the present study compared to the corresponding
values in the study by Cionca et al. [19] as well as by the fact that all patients in the present
study had at baseline over 9 sites with PD5mm (Table 3).
All three treatment groups obtained at 12 months statistically significant PD reductions
and CAL gain as compared to baseline. Nonetheless, the mean PD values at 12 months were
significantly lower in both AB groups as compared to placebo (p<0.05, Table 2). Mean PD
reductions and CAL gain were however statistically significantly higher only in the 7-day AB
group as compared to placebo. This might be due to the fact that this group presented at base-
line, even if statistically insignificant, deeper sites as compared to the other two groups (group
A and B) as seen from the baseline mean values for every PD category (total mean PD, PD 4-
6mm, PD>7mm, Table 2). Furthermore, the higher number of deep sites (PD7mm) at base-
line in the 7-day antibiotic group, even if statistically insignificant when compared to the other
two groups, might have influenced the outcomes for PD reductions and CAL gain, considering
that deeper sites might benefit more from an AB regimen compared to more shallow ones [15,
19, 26, 27, 32]. However, PD reductions for sites with PD between 4-6mm and for sites with
PD7mm were statistically significantly higher in both AB groups as compared to the placebo
group, with no statistically significant differences when comparing the 3- and the 7-day AB
groups (Table 2). Comparable results in terms of mean PD, were obtained by Feres et al. at 12
months (placebo: 3.05±0.59mm, AMX+MET for 14d: 2.54±0.40mm), by Cionca et al. at 6
months (placebo: 3.1±0.3mm, AMX+MET for 7 days 3.0±0.2mm) [19, 27]. Harks et al.
obtained at 27.5 months in both treatment groups slightly lower mean PD values as opposed
to the ones in the present study (Placebo: 2.6±0.7mm, AMX+MET for 7 days: 2.3±0.5mm)
[81], these differences being possibly explained by the baseline mean PD values, which were
about 2mm lower than those in our study (Table 2) and by the fact that they reported results of
a twice longer follow-up (27.5 months) compared to our study (12 months). Furthermore,
mean PD reductions obtained in our study in all treatment groups were similar to those
obtained in the SRP and AB groups of Goodson et al. at 24 months (SRP alone: 1.81±0.23mm,
SRP +AMX+MET for 14 days: 2.36±0.2 mm) [71]. Moreover, CAL gain in the AB group of
Goodson et al. (1.53±0.16 mm) was also comparable to that obtained in our study (3-day AB
group: 1.59±0.65, 7-day AB group: 1.71±0.54 mm). Slightly less CAL gain was observed by
Cionca et al., Feres et al. and Harks et al. [19, 27, 81]. These differences might be attributed to
the approximately 2 mm higher baseline CAL values in the patients included in the present
study as compared to those in the aforementioned studies.
Studies determining the clinical efficacy of a treatment use diverse criteria for defining suc-
cess [88] such as changes of PD and CAL, number and proportions of moderate to deep sites
[15, 16, 19, 27, 81]. Since ChP is an inflammatory disease initiated by bacterial infection, the
most important part of its therapy is the treatment of infection and elimination of inflamma-
tion to arrest disease progression and improve tooth prognosis. The use of full-mouth PD and
CAL as outcome variables in several studies [15, 17, 26, 27, 32] evaluating the effectiveness of
antibiotic treatment in non-surgical periodontal therapy may not be representative enough for
the effectiveness of an antibiotic treatment, since shallow sites have a lesser adjunctive benefit
from antibiotics as opposed to deep sites [15, 19, 26, 27, 32], and may not emphasize the treat-
ment effect for deep sites which have been shown to be at high risk for disease progression [64,
69, 89]. In this sense, mean PD and CAL values as well as their reductions/gain may not be the
most appropriate parameters for assessing the elimination of inflammation and effectiveness
of a treatment.
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Since disease progression is more likely to occur in deep sites, it seems relevant to evaluate
the residual number of such sites or changing the patient attribution from a severe to low risk
of disease progression. Considering this, we analysed both the residual number of deep sites
(PD6 mm) and patient attribution to risk for disease progression [69]. Irrespective of the
group allocation, all patients presented at baseline high risk for disease progression. After treat-
ment, the percentage of these patients decreased continuously in all groups up to 12 months. A
closer analysis of the risk distribution among groups revealed that almost half of the patients in
the placebo group were still at high risk for progression, while the 3-day AB group showed the
lowest number of patients with high risk. Finally, 70% of the patients in the 3-day AB group
reached a clinical endpoint of low disease progression (<4 sites with PD5 mm), followed by
the 7 days AB group with over 40% and by the placebo group with only 20%, which was statis-
tically significantly lower only compared to the 3-day AB group (PP analyses). Furthermore,
similar percentages for groups A and C were obtained for the number of patients that main-
tained a high risk for disease progression (9 sites with PD5 mm) and more sites PD5mm
at 12 months. The fact that group C didn‘t obtain in the PP-analyses significantly less patients
at low risk compared to group A may be related to the higher number of sites with PD5mm
and sites with PD6mm at baseline, even if this difference didn‘t reach statistical significance.
These values are comparable to those obtained in studies investigating this parameter: Feres
et al. at 12 months (Placebo: 22.5%, AMX+MET: 66.7%), Harks et al. at 27.5 months (Placebo
36.5%, AMX+MET: 63.1%) [27, 81].
In the present study, smokers exhibited at 12 months statistically significantly lower clinical
improvements as compared to non-smokers, and this was observed for most of the evaluated
parameters (Table 2). This is in line with data from other studies evaluating non-surgical peri-
odontal treatment that showed significantly lower clinical improvements in smokers [15, 90–
92]. Moreover, this is outlined in the results of the Poisson regression analyses (Table 4),
where smoking together with antibiotics (both 3- and 7-day antibiotic regimen), female gen-
der, BOP at baseline and 12 months, initial gingival marginal bleeding (GBI) and initial CAL
statistically influenced the residual number of sites with PD6mm at 12 months. This is in
agreement with other studies, where antibiotic treatment was found to be the only variable
that significantly influenced the clinical outcome [19, 27].
The trend for better clinical outcomes after 7 days of AMX and MET observed at 6 months
[11] was maintained at 12 months. As mentioned earlier and in our previous publication, we
sized the study with 30 subjects per treatment group in order to detect a difference of 5 sites
with PD6 mm [19, 27, 64] for a power of 90% (significance level 0.05). Since the present
study was designed as a superiority trial of the two antibiotic protocols over the mechanical
debridement alone, it cannot be ruled out that the direct comparison between the 3- and the
7-day protocol might be underpowered and therefore, this comparison should be interpreted
with caution. Thus, based on the present results, no conclusions regarding the direct compari-
son between the 3- and the 7-day antibiotic protocol can be drawn. Obviously, in order to ade-
quately address this important issue, future prospective, randomized, controlled clinical
studies with an appropriate design and including sufficient number of patients need to be
conducted.
A limitation of the present study represents the high attrition rate below 30 (according to
the initial study power calculation) recommending a careful interpretation of the present
results. The high dropout rate in all 3 groups was due to the facts that several patients either
omitted their follow-up appointments, have taken antibiotics in the follow-up period for other
medical reasons, or were further surgically treated (i.e. dental implants) by their referring den-
tists. The finding that at 12 months, the study has failed to reveal statistically significant differ-
ences for the main outcome variable between any of the treatment groups, may, on one hand,
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be related to the high attrition rate leading to a low study power at 12 months. However, on
the other hand, wide ranges for the standard deviation of the number of deep sites (PD6mm)
at baseline may have also influenced the results. Nonetheless, it has to be pointed out that the
majority of the investigated variables revealed statistically significantly better clinical improve-
ments (Table 2.) in both antibiotic groups compared to the placebo group, but these findings
need to be carefully interpreted being secondary outcomes.
In conclusion, the present study has shown that: a) in patients with severe chronic peri-
odontitis non-surgical periodontal therapy in conjunction with either three or seven days sys-
temic administration of amoxicillin (AMX) and metronidazole (MET) yields statistically
significantly greater clinical improvements compared to non-surgical therapy alone.
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